Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.